Health Topics — Neurological
Migraines and the Endocannabinoid System: What the Research Has Examined
A specific CSF anandamide finding in chronic migraineurs, the clinical endocannabinoid deficiency hypothesis, and a 2024 placebo-controlled trial — what each establishes and where the honest limits are for hemp-derived preparations.
Migraine is the third most prevalent illness globally and one of the most disabling — affecting approximately one billion people worldwide. Despite decades of research, its full pathophysiology remains incompletely understood. What is increasingly clear is that the endocannabinoid system is a significant regulatory node in migraine pathology, and that deficient endocannabinoid tone may underlie at least some forms of the condition.
The research here is more developed than in most areas of the cannabinoid archive — including a specific biological marker finding in human migraineurs and a completed placebo-controlled clinical trial. The honest framing requires a critical distinction: the human evidence that exists involves cannabis and THC, not hemp-derived CBD or CBG specifically.
The Trigeminal System and Why the ECS Is Relevant
Migraine pain originates in the trigeminal system — the network of sensory nerve fibers that innervate the meninges and meningeal blood vessels on the brain's surface. Migraine attacks are triggered by a cascade that activates these trigeminal nerve endings, which release calcitonin gene-related peptide (CGRP) and other inflammatory mediators into the meningeal tissue. This produces the characteristic intense, often unilateral throbbing pain of a migraine, alongside the nausea, photophobia, and phonophobia that accompany it.
Repeated migraine attacks alter the release patterns of these pain-inducing molecules, progressively sensitising the trigeminal system and lowering the threshold for subsequent attacks. This sensitisation process — similar in mechanism to the central sensitisation documented in chronic pain research — explains why migraine can progress from episodic to chronic, with attacks becoming more frequent and triggers becoming harder to avoid.
CB1 receptors are expressed on trigeminal nerve terminals. Endocannabinoid signalling modulates CGRP release and trigeminal pain transmission. The ECS is not a peripheral participant in migraine biology — it is expressed at the specific anatomical sites where migraine pain is generated and where sensitisation occurs.
The CSF Anandamide Finding
Study DesignCerebrospinal fluid (CSF) was obtained from 15 chronic migraine patients and 20 healthy controls. Anandamide levels were measured directly from CSF — the fluid surrounding the brain and spinal cord, providing a window into central nervous system biochemistry that blood measurements cannot offer.
FindingAnandamide levels in chronic migraineurs were 45% lower than in healthy controls. This is a specific, measurable biological deficit — not an association finding or a preclinical observation. It documents reduced endocannabinoid tone at the level of the central nervous system in people with chronic migraine.
SignificanceThis finding is the most direct human biological evidence supporting the clinical endocannabinoid deficiency (CED) hypothesis in migraine. Low CSF anandamide would predict reduced modulation of trigeminal pain signalling, lower pain thresholds, and greater vulnerability to the cascade that produces migraine attacks — which is consistent with the clinical picture of chronic migraine.
LimitationsThis is a small study (n=35 total). Correlation between low anandamide and chronic migraine does not establish causation — it is possible that low anandamide is a consequence rather than a cause of repeated migraine attacks, or that both reflect a shared underlying factor. Replication in larger populations has not been published.
The Clinical Endocannabinoid Deficiency Hypothesis in Migraine
Ethan Russo proposed the clinical endocannabinoid deficiency hypothesis in 2004 and revisited it in 2016, identifying migraine alongside fibromyalgia and irritable bowel syndrome as the three conditions with the most consistent evidence of deficient endocannabinoid tone. The hypothesis proposes that chronically low endocannabinoid signalling — whether from genetic factors, chronic stress, environmental exposures, or repeated depletion — reduces the threshold for migraine attacks by impairing the ECS's normal role in modulating trigeminal pain signals, serotonin function, and HPA axis stability.
The CSF anandamide finding provides the most direct biological support for this hypothesis in migraine. The co-occurrence of migraine with fibromyalgia and IBS — conditions that also have documented ECS involvement — is a pattern consistent with the hypothesis, though epidemiological co-occurrence is not mechanistic evidence.
The CED hypothesis is explicitly a hypothesis — Russo himself describes it as such throughout. It is not established clinical fact. What it provides is a coherent mechanistic framework for why endocannabinoid system support might be particularly relevant in chronic migraine, and why migraine frequency and severity might respond to interventions that raise endocannabinoid tone.
The 2024 Placebo-Controlled Clinical Trial
Study DesignA randomized controlled trial comparing vaporized cannabis flower versus placebo in participants with acute migraine. Presented at the 2025 American Headache Society Annual Meeting. This is the first placebo-controlled RCT of cannabis for acute migraine treatment.
FindingThe trial found evidence of efficacy for vaporized cannabis in reducing acute migraine pain. Subgroup analyses examined how different cannabis strains and ratios of THC to CBD affected outcomes. The full published analysis was being completed as of mid-2026.
Critical Distinction for Hemp PreparationsThe intervention was vaporized whole cannabis flower — containing meaningful THC concentrations. This is not equivalent to hemp-derived CBD or CBG preparations, which contain no significant THC. The trial cannot be used to support claims about hemp preparations. Earlier preclinical work in mice (Zorrilla et al., 2025, Cephalalgia) also found that CBD and THC together were more effective than either alone — reinforcing that the human trial's context involves the full cannabis phytochemical profile.
What It Does EstablishThat the ECS is a legitimate clinical target in migraine. That controlled research in this area is now underway and producing positive signals. That the biological rationale is strong enough to support an RCT. These are meaningful signals for the field even when the specific compound and route differ from hemp preparations.
CBD and CBG Specifically — What Is and Isn't Established
CBD inhibits FAAH — the enzyme that breaks down anandamide — raising anandamide levels throughout the body and brain. If depleted anandamide is a driver of migraine vulnerability, as the CSF finding and CED hypothesis suggest, then FAAH inhibition by CBD is a mechanistically coherent approach to addressing that deficit. This is the most direct case for hemp-derived CBD in the migraine context.
A preclinical study in mice found that CBD alone protected both male and female animals from CGRP-induced pain — the specific inflammatory mechanism driving trigeminal activation in migraine. CBD administered after CGRP reversed the pain behaviour. This is animal model evidence for a specific mechanism directly relevant to migraine pathophysiology.
CBG's relevance in migraine is more indirect. Its alpha-2 adrenoceptor activity reduces sympathetic nervous system output — which may reduce one category of migraine triggers for some people. Its anti-inflammatory mechanisms are not specific to the trigeminal system. CBG's most direct relevance to the migraine picture is through stress reduction — chronic stress is both a migraine trigger and a driver of HPA-HPG dysregulation that may further deplete endocannabinoid tone.
No controlled human trial of CBD alone or CBG for migraine has been published as of July 2026.
The Honest Distance from This Research to Our Preparations
The CSF anandamide finding establishes a biological deficit in chronic migraineurs. CBD's FAAH inhibition raises anandamide. The step connecting these two facts — that CBD preparations reliably and meaningfully raise CSF anandamide in migraineurs, and that this reduces attack frequency or severity — has not been tested in a human trial.
The whole-plant CBD preparations we make contain CBD in a whole-plant context alongside other phytochemicals. Whether this preparation meaningfully influences anandamide tone in the central nervous system — and whether that influence is sufficient to affect migraine in a clinically meaningful way — is unknown. The biological case for asking the question is strong. The answer has not been found.
What This Research Establishes and What It Doesn't
Chronic migraineurs have measurably lower CSF anandamide than healthy controls — a specific human biological finding supporting the CED hypothesis. The ECS is expressed in the trigeminal system and modulates the pain cascade that produces migraine. A placebo-controlled RCT found vaporized cannabis effective for acute migraine — but using THC-containing cannabis, not hemp-derived CBD. Preclinical CBD research in migraine models is positive and mechanistically grounded.
No controlled human trial of CBD alone or CBG for migraine prevention or treatment exists. Hemp-derived preparations cannot be positioned as migraine treatments. The CED framework provides a coherent biological rationale for ECS support in chronic migraine; it does not substitute for controlled trial evidence.
For a person with frequent migraines who is considering a hemp preparation: the mechanistic case is among the strongest in this archive. The evidence that the mechanism translates to clinical benefit from hemp-specific preparations has not been generated.
References
- Sarchielli, P., Rainero, I., Coppola, F., et al. (2007). Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology, 32(6), 1384–1390.
- Russo, E.B. (2004). Clinical endocannabinoid deficiency (CED): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinology Letters, 25(1-2), 31–39.
- Russo, E.B. (2016). Clinical endocannabinoid deficiency reconsidered: Current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis and Cannabinoid Research, 1(1), 154–165.
- Schuster, N.M., et al. (2024). Vaporized cannabis versus placebo for acute migraine: A randomized controlled trial. medRxiv preprint. Presented at American Headache Society Annual Meeting 2025.
- Zorrilla, I., et al. (2025). Combined effects of cannabidiol and Δ9-tetrahydrocannabinol alleviate migraine-like symptoms in mice. Cephalalgia, 45(2), 3331024251314487.
- Biringer, R.G. (2025). Treatment of migraine with phytocannabinoids, the involvement of endocannabinoids in migraine, and potential mechanisms of action. Pain Research and Management, 2025, 7181066.
- Greco, R., Gasperi, V., Maccarrone, M., & Tassorelli, C. (2010). The endocannabinoid system and migraine. Experimental Neurology, 224(1), 85–91.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.